Monoclonal Antibody Therapy in Alzheimer’s Disease
Pharmaceutics · 29.12.2023 · 16 (1) · 60
DOI: 10.3390/pharmaceutics16010060 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 29.12.2023. Verfasst von Monica Neațu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neurosciences, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 183 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: “Carol Davila” University of Medicine and Pharmacy Bucharest, Romania, Department of Research and Grants Romania through funding by the Ministry of Research an….
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease is a neurodegenerative condition marked by the progressive deterioration of cognitive abilities, memory impairment, and the accumulation of abnormal proteins, specifically beta-amyloid plaques and tau tangles, within the brain. Despite extensive research efforts, Alzheimer’s disease remains without a cure, presenting a significant global healthcare challenge. Recently, there has been an increased focus on antibody-based treatments as a potentially effective method for dealing with Alzheimer’s disease. This paper offers a comprehensive overview of the current status of research on antibody-based molecules as therapies for Alzheimer’s disease. We will briefly mention their mechanisms of action, therapeutic efficacy, and safety profiles while addressing the challenges and limitations encountered during their development. We also highlight some crucial considerations in antibody-based treatment development, including patient selection criteria, dosing regimens, or safety concerns. In conclusion, antibody-based therapies present a hopeful outlook for addressing Alzheimer’s disease. While challenges remain, the accumulating evidence suggests that these therapies may offer substantial promise in ameliorating or preventing the progression of this debilitating condition, thus potentially enhancing the quality of life for the millions of individuals and families affected by Alzheimer’s disease worldwide.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Neurosciences, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
- Department of Neurology, Colentina Clinical Hospital, 020125 Bucharest, Romania.
- Department of Cell Biology, Neurosciences and Experimental Myology, "Victor Babeș" National Institute of Pathology, 050096 Bucharest, Romania.
ORCID-Profile: Eugenia Irene Davidescu, Bogdan Ovidiu Popescu
Förderung
- “Carol Davila” University of Medicine and Pharmacy Bucharest, Romania, Department of Research and Grants Romania through funding by the Ministry of Research an…
Zitieren
APA
Neațu, M., Covaliu, A., Ioniță, I., Jugurt, A., Davidescu, E. I., & Popescu, B. O. (2023). Monoclonal Antibody Therapy in Alzheimer’s Disease. Pharmaceutics, 16(1), 60. https://doi.org/10.3390/pharmaceutics16010060
Vancouver
Neațu M, Covaliu A, Ioniță I, Jugurt A, Davidescu EI, Popescu BO. Monoclonal Antibody Therapy in Alzheimer’s Disease. Pharmaceutics. 2023;16(1):60. doi:10.3390/pharmaceutics16010060
BibTeX
@article{Neau2023,
author = {Neațu, Monica and Covaliu, Anca and Ioniță, Iulia and Jugurt, Ana and Davidescu, Eugenia Irene and Popescu, Bogdan Ovidiu},
title = {Monoclonal Antibody Therapy in Alzheimer’s Disease},
journal = {Pharmaceutics},
year = {2023},
volume = {16},
number = {1},
pages = {60},
doi = {10.3390/pharmaceutics16010060}
}
EUVIMED